By Mark JohnsonThe hair relaxer MDL in the Northern District of Illinois has exploded to over 8,000 lawsuits, marking a huge shift in beauty industry litigation and forcing a hard look at product safety claims. This isn’t business as usual. This sheer number of cases means a real reckoning is coming for manufacturers, and it’s the start of a tough legal fight for the plaintiffs who are seeking justice.
Key Takeaways
- In February 2023, the Judicial Panel on Multidistrict Litigation created MDL No. 3060, consolidating over 8,000 hair relaxer lawsuits under Judge Mary M. Rowland in the Northern District of Illinois.
- The core of these lawsuits is the claim that long-term use of chemical hair relaxers directly caused serious health conditions like uterine cancer, ovarian cancer, uterine fibroids, and endometriosis, with the 2022 NIH Sister Study being a central piece of evidence.
- Discovery is moving quickly in the MDL. Bellwether cases have already finished initial fact discovery, and expert discovery is now in motion, showing a clear push from the court toward trials or a global settlement.
- Big names like L’Oréal, Revlon, and Strength of Nature are on the hook for what could be billions of dollars in liability, not to mention massive reputational damage, if the plaintiffs’ arguments hold up in court.
- Anyone who used chemical hair relaxers for a long time and later developed reproductive health problems needs to talk to a lawyer right away to see if they can join the MDL.
The Consolidation of 8,000+ Cases: MDL No. 3060
The scale of the hair relaxer MDL, formally titled In re: Hair Relaxer Products Liability Litigation (MDL No. 3060), is frankly astonishing. Court dockets and orders from the Judicial Panel on Multidistrict Litigation (JPML) confirm that by late 2025, the case count in the Northern District of Illinois has shot past 8,000. This number of claims piled up incredibly fast since the MDL was formed in February 2023. To put that in perspective, many major product liability MDLs take years to get to that size, if they ever do. The velocity here points to a massive, underlying consumer concern and a very strong story of alleged harm.
My read on this rapid consolidation is simple: the legal community believes these cases have serious merit. These aren’t just speculative shots in the dark. Lawyers are responding to a real public outcry that’s backed by scientific research and thousands of personal stories. The JPML’s move to put all these cases under Judge Mary M. Rowland shows they agree that the common questions of fact, about how the products were designed, made, and marketed, and especially about scientific causation, are better handled in one court. This structure makes discovery more efficient, prevents conflicting rulings, and puts enormous pressure on the defendants to start talking about a real settlement.
The 2022 NIH Sister Study: A Scientific Catalyst
The entire litigation field shifted when the National Institutes of Health (NIH) Sister Study published its findings in October 2022. The study, which appeared in the Journal of the National Cancer Institute, dropped a bombshell: women who frequently used hair straightening products were more than twice as likely to develop uterine cancer as women who didn’t. Drilling down, the data showed that women using chemical hair relaxers over four times a year faced a 2.5-fold increased risk of uterine cancer. This was a statistically powerful finding coming from a respected, long-running study of more than 33,000 women.
The smoothest skin you've ever had, no razor required
Skip the daily shave. Find a top-rated waxing studio near you and book your first visit in minutes.
Find a Wax Studio Near You →This kind of scientific data completely changes the calculus for a mass tort lawsuit. Before this NIH study came out, any case trying to connect hair relaxers to cancer was built on personal stories and smaller, less definitive studies. The Sister Study delivered a powerful, peer-reviewed scientific foundation for the plaintiffs’ causation argument. It gave attorneys the proof they needed to argue that these products were potentially carcinogenic chemicals, not just simple cosmetics. I have no doubt that without this study, we wouldn’t be looking at an MDL with 8,000+ plaintiffs. It’s a perfect example of science forcing a legal reckoning.
Projected Economic Impact: Billions at Stake
No official settlement offers are on the table yet, but my conversations with other legal experts and industry analysts all point to one thing: potential liability that will easily run into the billions of dollars. You just have to look at the number of plaintiffs and the severity of the injuries being alleged (uterine cancer, ovarian cancer, uterine fibroids, endometriosis), then factor in the possibility of punitive damages. A single successful case could bring an award from hundreds of thousands to several million dollars, and if you multiply that by 8,000 or more, the financial exposure is immense.
The fallout goes way beyond direct payments to plaintiffs. Defendants like L’Oréal, Revlon, and Strength of Nature are already seeing their stock prices get jumpy, and their entire market position is being questioned. Beyond the settlement checks, they’re facing huge legal bills, brand damage that could take years to repair, and the possibility of having to reformulate or pull products off the shelf entirely. It feels a lot like the asbestos or opioid litigation, where the financial hit on entire industries lasted for a generation. This is a brutal lesson for any manufacturer: you can’t ignore the emerging science and hope it goes away.
Discovery Milestones: A Path Towards Resolution
This MDL is not sitting still. The court is pushing an aggressive schedule, and we’ve already passed several key discovery milestones. As of late 2025, the first group of bellwether cases has mostly wrapped up initial fact discovery, which means mountains of documents have been produced and key corporate officers have sat for depositions. Judge Rowland has also laid out a tight timeline for expert discovery, with plaintiffs’ expert reports on causation due in early 2026, followed quickly by the defense experts’ reports. This is the heart of the case. The whole MDL will turn on the expert testimony about general causation (can these products cause these diseases?) and specific causation (did the product cause this specific plaintiff’s disease?).
My take is that Judge Rowland is actively steering this ship toward a resolution, either through early bellwether trials or a massive global settlement. She is not letting this case get bogged down, which is a common problem in litigation this complex. By fast-tracking the expert phase, the court is forcing both sides to put their scientific cards on the table. I expect we could see the first trials get underway in Chicago in late 2026 or early 2027. The outcomes of those trials will be a huge signal to both sides about jury reception to the evidence, which will in turn drive settlement talks for the other 7,900+ cases. Both sides are investing a fortune in their expert witnesses right now.
Challenging Conventional Wisdom: The “Safe” Product Myth
For decades, the common belief, especially among women who used them, was that hair relaxers were just a normal part of a beauty routine. They were sold everywhere, used by millions, and assumed to be safe if you followed the directions. That whole perception was built on decades of marketing and a general failure to communicate chemical risks to the public. The hair relaxer MDL is tearing that myth apart.
I’ve never bought the idea that these products were truly “safe” for repeated, long-term use. For years, the body of research on endocrine-disrupting chemicals (EDCs) and their health effects has been growing. Chemicals commonly used in relaxers, like certain phthalates and formaldehyde-releasers, have been on the radar of environmental health scientists for a long time. The beauty industry, like many others, has a pattern of prioritizing marketability and cosmetic results over deep, long-term health studies. This litigation is a blunt reminder that just because something is legal to sell doesn’t mean it’s biologically harmless. Consumers were sold a story about safety that science is now showing was, at a minimum, an exaggeration and, at worst, a complete deception. We’re not talking about a few bad batches. This is about the core formulas and the failure to warn, and the industry has a lot to answer for.
The hair relaxer MDL is a major battle over consumer safety that’s forcing companies to finally confront the serious health claims tied to their products. If you used these products for years and have since been diagnosed with related health problems, you should speak with a qualified attorney to see what your legal options are and if you can be included in the MDL.
What’s an MDL for these hair relaxer lawsuits?
An MDL (Multidistrict Litigation) is a federal court procedure that gathers many similar lawsuits filed in different courts across the country into a single district court. In this instance, MDL No. 3060 pulls all federal lawsuits claiming injuries from chemical hair relaxers before one judge in the Northern District of Illinois. The goal is to make all the pretrial work, like discovery, more efficient and consistent.
What specific health problems are being alleged?
The plaintiffs’ main allegation is that long-term, frequent use of chemical hair relaxers led to serious reproductive health issues. The primary injuries cited are uterine cancer, ovarian cancer, uterine fibroids, and endometriosis, and the lawsuits point to scientific research like the NIH Sister Study as proof.
Which companies are being sued in the MDL?
A number of major beauty companies are named as defendants. The key players are L’Oréal USA, Inc., Revlon, Inc., and Strength of Nature Global, LLC, along with other companies that manufactured, marketed, or sold these chemical hair relaxer products.
How does the 2022 NIH Sister Study affect this litigation?
The 2022 NIH Sister Study is a key piece of evidence for the plaintiffs. Its conclusion that frequent use of hair straightening products was linked to a significantly higher risk of uterine cancer provides a strong scientific backbone for the plaintiffs’ argument that the products caused their health problems.
What should I do if I think I have a hair relaxer claim?
If you used chemical hair relaxers over a long period and were later diagnosed with uterine cancer, ovarian cancer, uterine fibroids, or endometriosis, you should contact an attorney who works on mass tort or product liability cases. A lawyer can review the details of your case, see if you are eligible to join the MDL, and explain the legal process.
